Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Phase 1 To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of tazemetostat as a single agent administered orally twice daily (BID), continuously in 28-day cycles, in subjects with advanced solid tumors or with relapsed and/or refractory B cell lymphomas Phase 2 To determine the objective response rate (ORR; complete response + partial response [CR + PR]) of tazemetostat in subjects with enhancer of zeste homolog 2 (EZH2) gene mutation positive or negative (wild-type) with histologically confirmed diffuse large B cell lymphoma (DLBCL) or follicular lymphomas (FL), with relapsed or refractory disease.
Critère d'inclusion
- Relapsed or refractory Diffuse Large B Cell Lymphoma, Follicular
- Lymphoma, Advanced solid tumor